Staf-50 Inhibitors
Chemical inhibitors of Staf-50 can function through various mechanisms to inhibit its activity within different cellular pathways. MG-132 and Bortezomib, both proteasome inhibitors, can lead to the accumulation of ubiquitinated proteins, which is a key process that Staf-50 is involved in. By inhibiting the proteasome, these chemicals effectively prevent the degradation and recycling of proteins that Staf-50 may tag for destruction, thereby inhibiting its function. Similarly, Epoxomicin serves this role by irreversibly binding to proteasomes, ensuring that proteins which Staf-50 has marked are not broken down. This build-up of proteins can disrupt the normal function of Staf-50 as it is unable to complete its role in the ubiquitin-proteasome system.
Curcumin and Chloroquine target pathways that are also crucial to Staf-50's function. Curcumin inhibits the NF-κB pathway, which is closely tied to the immune response and apoptosis, processes in which Staf-50 is implicated. By inhibiting NF-κB, Curcumin indirectly inhibits Staf-50's ability to modulate these responses. Chloroquine, by increasing the pH of acidic vesicles, can impair cellular degradation pathways, including those that Staf-50 may be involved in, leading to its functional inhibition. E-64's inhibition of cysteine proteases also affects the degradation pathway, potentially inhibiting Staf-50. Withaferin A disrupts the cytoskeletal network and could affect Staf-50. The MAP kinase inhibitors PD98059, SB203580, and SP600125 inhibit MEK, p38, and JNK, respectively. As these kinases are involved in a variety of cellular responses, including inflammatory and stress responses, their inhibition can lead to the functional inhibition of Staf-50. Lastly, LY294002 inhibits PI3K, a kinase involved in a broad array of cellular functions, and its inhibition can impact Staf-50's activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Staf-50 is implicated in ubiquitin-related processes, and inhibition of the proteasome can lead to the functional inhibition of Staf-50 by preventing its degradation through the ubiquitin-proteasome pathway. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib specifically targets and inhibits the 26S proteasome. Given that Staf-50 is involved in the ubiquitin-proteasome system, inhibition of proteasomal activity by Bortezomib would result in the accumulation of proteins, indirectly inhibiting the function of Staf-50. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has been shown to inhibit the NF-κB pathway, which is often involved in the regulation of immune responses and apoptosis. As Staf-50 has roles in immune response modulation, Curcumin's inhibition of NF-κB can lead to the functional inhibition of Staf-50. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is known to raise the pH of acidic vesicles within cells, impairing processes like protein degradation. If Staf-50 is involved in the endosomal/lysosomal pathway, Chloroquine's disruption of this pathway would result in the functional inhibition of Staf-50. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is an irreversible cysteine protease inhibitor. If Staf-50 function depends on the action of cysteine proteases, the inhibition of these enzymes by E-64 could lead to the functional inhibition of Staf-50 activity. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $130.00 $583.00 $4172.00 $20506.00 | 20 | |
Withaferin A disrupts the cytoskeletal network by binding to annexins, which could potentially inhibit the trafficking or localization of Staf-50 within the cell, leading to its functional inhibition. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a potent, irreversible proteasome inhibitor. By inhibiting the proteasome, it would cause the accumulation of ubiquitinated proteins and could indirectly inhibit Staf-50's function if Staf-50 is involved in protein turnover through the ubiquitin-proteasome system. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is upstream of ERK in the MAP kinase pathway. Since Staf-50 is involved with immune responses, inhibiting MEK and therefore the MAPK pathway could lead to the functional inhibition of Staf-50 by impeding signaling required for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase. By inhibiting p38, a kinase involved in inflammatory responses, SB203580 could inhibit Staf-50's function in the immune response if Staf-50 operates within this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, another member of the MAPK family. By inhibiting JNK, SP600125 could lead to functional inhibition of Staf-50 if it is involved in signaling pathways regulated by JNK activity. | ||||||